Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: Results from two randomised, placebo-controlled phase III studies

British Journal of Cancer

Volumn 90, Issue 6, 2004, Pages 1133-1137

  Body, J J ^a   Diel, I J ^b   Liehinitzer, M ^c   Lazarev, A ^d   Pecherstorfer, M ^e   Bell, R ^f   Tripathy, D ^g   Bergstrom, B ^h  

^a JULES BORDET INSTITUTE   (Belgium)

^b CGG Klinik GmbH   (Germany)

^c Cancer Research Center   (Russian Federation)

^d Oncological Center   (Russian Federation)

^e WILHELMINEN HOSPITAL   (Austria)

^f Andrew Love Cancer Centre   (Australia)

^g UNIVERSITY OF TEXAS AT DALLAS   (United States)

^h HOFFMANN LA ROCHE INC   (United States)

Author keywords

Bone metastases; Breast cancer; Ibandronate; Oral bisphosphonate; Skeletal complications

Indexed keywords

IBANDRONIC ACID; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG TOLERABILITY; DUODENUM BLEEDING; DYSPEPSIA; ESOPHAGITIS; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HYPOCALCEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NAUSEA; NEPHROTOXICITY; PHASE 3 CLINICAL TRIAL; POISSON DISTRIBUTION; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RISK ASSESSMENT;

EID: 1942501727     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601663     Document Type: Article

References (23)

1. Body JJ (2003) Effectiveness and cost of bisphosphonate therapy in tumor bone disease. Cancer 97(Suppl): 859-865
2. Body JJ, Diel IJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, Budde M, Bergström B (2003a) On behalf of the MF 4265 Study Group. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14: 1399-1405
3. Body JJ, Diel I, Tripathy D, Bergstrom B (2003b) Impact of ibandronate on bone pain in patients with metastatic bone disease from breast cancer. Support Care Cancer 11: 395-396 (abstract A-34)
4. Body JJ, Kanis J, Diel I, Bergstrom B (2003c) Risk reductions in metastatic breast cancer: multivariate Poisson regression analyses of oral and i.v. ibandronate. Proc ASCO 22: 46 (abstract 184)
5. Diel I, Bell R, Tripathy D, Body JJ, Bergström B (2003) Renal safety of oral and intravenous ibandronate in metastatic bone disease: phase III clinical trial results. Support Care Cancer 11: 415 (abstract A-106)
6. Green JR, Muller K, Jaeggi KA (1994) Preclinical pharmacology of CGP 42446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 9: 745-751
7. Hillner BE, Ingle JN, Berenson JR, Janjan NA, Albain KS, Lipton A, Yee G, Biermann JS, Chlebowski RT, Pfister DG (2000) American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 18: 1378-1391
8. Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, Wheeler H, Simeone JF, Seaman JJ, Knight RD, Heffernan M, Mellars K, Reitsma DJ (1998) Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 16: 2038-2044
9. Jonckheere AR (1954) A distribution-free k-sample test against ordered alternatives. Biometrika 41: 133-145
10. Kristensen B, Ejlertsen B, Groenvold M, Hein S, Loft H, Mouridsen HT (1999) Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med 246: 67-74
11. Leyland-Jones B. Pharmacokinetic and clinical equivalence of oral and intravenous ibandronate for metastatic bone disease. Eur J Cancer, in press
12. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long-term follow-up of two randomized, placebo-controlled trials. Cancer 88: 1082-1090
13. Lyubimova N, Kushlinsky NE, Lichinitser MR (2003) Long-term treatment with intravenous ibandronate does not effect renal function in breast cancer patients with metastatic bone disease. Support Care Cancer 11: 416 (abstract A-107)
14. Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S (1993) Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11: 59-65
15. Pavlakis N, Stockler M (2002) Bisphosphonates in breast cancer [Cochrane Review]. Cochrane Database Syst Rev 1: CD003474
16. Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, Rosenquist K, Smith I, Ortestad L, Legault S, Pajunen M, Nevankaus S, Mannisto E, Suovuori A, Atula S, Nevalainen J, Pylkkanen L (2002) Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 20: 3219-3224
17. Robertson AG, Reed NS, Ralston SH (1995) Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J Clin Oncol 13: 2427-2430
18. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey JA, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7: 377-387
19. Ross JR, Saunders Y, Edmonds PM, Patel S, Broadley KE, Johnston SR (2003) Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 327: 469
20. Scott M, Möcks J, Givens S, Köhler W, Maurer J, Budde M (2003) Morbidity measures in the presence of recurrent composite endpoints. Pharm Stat 2: 39-49
21. Terpstra TJ (1952) The asymptotic normality and consistency of Kendall's test against trend, when ties are present in one ranking. Indag Math 14: 327-333
22. Theriault SL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, Costello S, Kennedy I, Simeone J, Seaman JJ, Knight RD, Mellars K, Heffernan M, Reitsma DJ (1999) Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomised, placebo-controlled trial. J Clin Oncol 17: 846-854
23. Tripathy D, Pecherstorfer M, Bartl R, Bell R, Diel I, Bergström B (2003) Reduction in risk of skeletal events with ibandronate in the treatment of metastatic breast cancer. Support Care Cancer 11: 427 (abstract A-152)